Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 5 - Drugs for disorders of the endocrine system
Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908)
09/2000
09/28/2000CA2368047A1 Chemokine receptor binding heterocyclic compounds
09/28/2000CA2367488A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000CA2366926A1 Pharmaceutical compositions comprising dipeptidy peptidase iv inhibitors for the promotion of growth
09/28/2000CA2366267A1 49 human secreted proteins
09/28/2000CA2365223A1 46 human secreted proteins
09/27/2000EP1038863A2 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof
09/27/2000EP1038016A2 Needle-free injection of formulated nucleic acid molecules
09/27/2000EP1037655A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
09/27/2000EP1037587A1 Site-specific preparation of polyethylene glycol-grf conjugates
09/27/2000CN1268120A Novel dihydronaphthalene compound and process and producing the same
09/26/2000US6124309 Method and pharmaceutical composition for regulating lipid concentration
09/26/2000US6124264 Growth hormone secretagogue in a human or other animal to treat osteoporosis, congestive heart failure, aging, obesity; bone and wound healing agents
09/26/2000US6124263 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
09/21/2000WO2000055634A1 Grb14 and the insulin receptor and screening of novel medicines
09/21/2000WO2000055201A1 49 human secreted proteins
09/21/2000WO2000055190A1 Novel lhrh antagonists with improved solubility characteristics
09/21/2000WO2000055155A2 Heterocyclic compounds as adenosine deaminase inhibitors
09/21/2000WO2000055147A1 Fused 1,4-thiazine-2-carbonitrile derivatives, their preparation and use
09/21/2000WO2000055137A1 Compounds and methods for modulation of estrogen receptors
09/21/2000WO2000055133A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors
09/21/2000WO2000055126A2 N-cyanomethylamides as protease inhibitors
09/21/2000WO2000055125A2 N-cyanomethyl amides as protease inhibitors
09/21/2000WO2000055120A1 Amide derivatives
09/21/2000WO2000055118A1 Nuclear receptor arylating compounds
09/21/2000WO2000055072A2 Aerosol metering valve
09/21/2000WO2000054806A1 Insulin-like growth factor binding protein-4 protease
09/21/2000WO2000054780A2 Corticosteroid formulation
09/21/2000WO2000054763A2 Pharmaceutical compositions comprising polymorphic forms of dehydroepiandrosterone
09/21/2000WO2000039077A3 Thyroid receptor ligands
09/21/2000WO2000026227A9 Ldl related protein and uses thereof
09/21/2000CA2368150A1 1-acyl-7-nitroindoline derivatives, their preparation and their use as photocleavable precursors
09/21/2000CA2368148A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2368122A1 Novel compounds and compositions as protease inhibitors
09/21/2000CA2367895A1 Compounds and methods for modulation of estrogen receptors
09/21/2000CA2367409A1 Metering valve
09/21/2000CA2363022A1 49 human secreted proteins
09/21/2000CA2361819A1 Amide derivatives
09/21/2000CA2361503A1 Corticosteroid formulation
09/21/2000CA2332767A1 Dhea composition and method
09/20/2000EP1036065A1 Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors
09/20/2000EP0586549B1 Selecting ligand agonists and antagonists
09/20/2000CN1056611C Pyrazolo and pyrrolopyridines, their use and intermidiates for preparing same
09/19/2000US6121449 Testosterone 5 alpha-reductase inhibitory activity; useful in therapy in the treatment of hyperandrogenic conditions
09/19/2000US6121375 Gels formed by the interaction of poly(aldehyde) with various substances
09/19/2000US6121312 Cyclic ether vitamin D3 compounds and uses thereof
09/19/2000US6121295 Treating diabetic complications by administering an insulin sensitivity enhancer such as pioglitazone in combination with a statin compound such as pravastatin
09/19/2000US6121294 Reducing the amount of therapeutic agents administered to a diabetic patient by administering an insulin sensitivity enhancer in combination with an alpha-glucosidase inhibitor as said therapeutic agents; side effect reduction
09/19/2000US6121293 Benzothiophene compounds, compositions, and methods
09/19/2000US6121253 Prostaglandin conjugates for treating or preventing bone disease
09/19/2000US6121016 DNA encoding human follicle stimulating hormone receptor, vectors and cells containing such DNA, and methods of use thereof
09/19/2000CA2071538C Hpth (1-37) fragment, its production, drug containing it and its use
09/14/2000WO2000053619A1 14.beta., 17-alpha-hydroxymethylandrostane derivatives as androgens
09/14/2000WO2000053602A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000WO2000053185A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000WO2000053181A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000WO2000053180A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000WO2000053178A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000WO2000037422A3 Ion channel modulating agents
09/14/2000WO2000037109A3 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions
09/14/2000WO2000037065A3 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
09/14/2000WO2000031263A3 Gtpase associated proteins
09/14/2000CA2367130A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2367126A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2367121A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2367113A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2366615A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2359218A1 14.beta., 17-alpha-hydroxymethylandrostane derivatives as androgens
09/13/2000EP1033990A1 21-hydroxy-6,19-oxidoprogesterone (21oh-6op) and its use as medicament for treating excess of glucocorticoids
09/13/2000EP0764166B1 Corticotropin releasing factor antagonists
09/13/2000CN1056295C Tradtional Chinese medicine for balancing internal secretion
09/12/2000US6117893 Heterocyclic compounds having anti-diabetic activity and their use
09/12/2000US6117838 Administering from about 30 to about 1,225 milligrams of intermolecularly- or intramolecularly-crosslinked stroma-free hemoglobin per kilogram of body weight to the mammal
09/12/2000US6117421 Method for promoting cell growth and immunosuppression using chaperonin
09/08/2000WO2000052145A2 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
09/08/2000WO2000052049A2 A method for purifying human growth hormone
09/08/2000WO2000052028A1 TUMOR NECROSIS FACTOR RECEPTORS 6α and 6$g(b)
09/08/2000WO2000051982A1 N-substituted indolines as estrogenic agents
09/08/2000WO2000051971A1 Oxamic acids and derivatives as thyroid receptor ligands
09/08/2000WO2000029583A3 Immunoglobulin superfamily proteins
09/08/2000CA2364911A1 N-substituted indolines as estrogenic agents
09/08/2000CA2364415A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
09/08/2000CA2364030A1 A method for purifying human growth hormone
09/06/2000EP1033364A1 Cyano containing oxamic acids and derivatives as thyroid receptor ligands
09/06/2000EP1032667A2 A33-related antigens and their pharmacological uses
09/06/2000EP1032584A1 Novel 19-nor steroids substituted in position 11beta, preparation method and intermediates, application as medicines and pharmaceutical compositions containing them
09/06/2000EP1032423A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
09/06/2000EP1032399A1 Progestin therapy with controlled bleeding
09/06/2000EP1032396A1 New composition of matter
09/05/2000US6114517 Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
09/05/2000US6114318 17β-(2-oxo-tetrahydrofuranyl)-thio- substituted androstane derivatives
09/05/2000US6114317 Method of locking 1α-OH of vitamin D compounds in axial orientation
09/05/2000US6113899 Antagonists of chaperonin 10
08/2000
08/31/2000WO2000050641A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION
08/31/2000WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease
08/31/2000WO2000050456A2 Covalently bridged insulin dimers
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050046A1 Stabilized oral pharmaceutical composition containing iodide and iodate and method
08/31/2000WO2000049937A2 Trpm-2 antisense therapy
08/31/2000WO2000030623A3 Agent for lowering prolactin
08/31/2000WO2000026236A3 Method of modulating cell differentiation or neoplastic transformation by altering cadherin-11 expression or function
1 ... 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 ... 290